OSR Holdings Provides Transparency Update on Equity Financing Instruments

Rhea-AI Summary

OSR Holdings (NASDAQ: OSRH) has provided a detailed update on its equity financing instruments, particularly focusing on its Equity Line of Credit (ELOC) agreement with White Lion GBM Innovation Fund. The company has issued 2,308,382 total shares under structured financing, including 519,481 commitment shares, 745,193 convertible notes, and 276,208 warrant exercises.

Under the ELOC agreement, which has a registered share capacity of 9,500,000, only 767,500 shares have been issued since June 17, 2025, representing less than 10% utilization. The company emphasized that proceeds are being invested in their drug R&D pipeline, medical device initiatives, and digital asset ecosystems.

Additionally, OSRH revealed that Woori IO's clinical trial in Korea is being conducted in partnership with a major technology company in mobile and wearable devices, with the Stock Purchase Agreement expected to complete by October.

Positive

• Limited dilution with less than 10% of registered shares issued under ELOC
• Strategic partnership with major tech company for Woori IO clinical trials
• Diverse portfolio including cancer immunotherapy platform and osteoarthritis drug candidate
• Structured financing proceeds directly support R&D pipeline development

Negative

• Ongoing share dilution through ELOC, warrants, and convertible notes
• 2.3 million shares already issued under structured financing
• Current share price reportedly below company's intrinsic value
• Woori IO acquisition still pending completion

News Market Reaction – OSRH

-20.44%

18 alerts

-20.44% News Effect

-25.3% Trough in 32 hr 41 min

-$4M Valuation Impact

$17M Market Cap

0.9x Rel. Volume

On the day this news was published, OSRH declined 20.44%, reflecting a significant negative market reaction. Argus tracked a trough of -25.3% from its starting point during tracking. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $17M at that time.

Data tracked by StockTitan Argus on the day of publication.

BELLEVUE, Wash., July 31, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical innovation approaches to health and wellness to support global health outcomes, today provided a transparency update regarding its Equity Line of Credit (ELOC) agreement with White Lion GBM Innovation Fund and related convertible instruments.

Highlights:

• Total shares issued to date under structured financing: 2,308,382
  • Commitment Shares: 519,481
  • Convertible Notes: 745,193
  • Warrant Exercises: 276,208
    
    
• Under the ELOC agreement:
  • Registered Share Capacity: 9,500,000
  • Shares Issued Since June 17, 2025 (Effecitve Date of S-1/A): 767,500
  • Utilization: Less than 10% of total registered shares

"While structured financing mechanisms like ELOCs, warrants, and convertible notes inherently carry dilution risk, it's important to emphasize that any future issuance under our ELOC is not purely dilutive," said Peter Hwang, CEO of OSRH. "Proceeds from these financings are being invested directly into our business, enabling accelerated development across our drug R&D pipeline, medical device initiatives, and digital asset ecosystems."

Dilution to date has been limited and tightly managed, with less than 10% of registered shares issued under the ELOC. OSRH is committed to protecting shareholder value by aligning all financing activity with near-term growth objectives.

OSRH remains confident that its current share price does not reflect the company's intrinsic value, which includes:

• A "Plug-and-Play" bacterial vector platform for cancer immunotherapy
• A Disease-Modifying Osteoarthritis Drug (DMOAD) candidate
• A strategic move toward acquiring noninvasive glucose monitoring technology through a signed term sheet with Woori IO

Woori IO Transaction Update:

"While not disclosed in our initial announcement, Woori IO's clinical trial in Korea is being conducted in partnership with one of the world's largest technology companies in the mobile and wearable devices space," said Mr. Hwang. "We intend to provide full transparency on this relationship following the signing of the Stock Purchase Agreement, which we expect to complete in good faith by the end of October."

About OSR Holdings, Inc.

OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness to support global health outcomes. Through its subsidiaries, OSRH is engaged in immuno‑oncology, regenerative biologics, and medical device distribution. OSRH's vision is to acquire and operate a portfolio of innovative healthcare and wellness companies, improving patient care through cutting‑edge research and development. For more information, visit www.OSR‑Holdings.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/osr-holdings-provides-transparency-update-on-equity-financing-instruments-302518896.html

SOURCE OSR Holdings Inc.

FAQ

How many shares has OSRH issued under its structured financing to date?

OSRH has issued a total of 2,308,382 shares under structured financing, including 519,481 commitment shares, 745,193 convertible notes, and 276,208 warrant exercises.

What is the current utilization rate of OSRH's Equity Line of Credit (ELOC)?

OSRH has utilized less than 10% of the total 9,500,000 registered shares under the ELOC agreement, with 767,500 shares issued since June 17, 2025.

What are the key assets in OSRH's portfolio?

OSRH's portfolio includes a bacterial vector platform for cancer immunotherapy, a Disease-Modifying Osteoarthritis Drug candidate, and pending acquisition of noninvasive glucose monitoring technology through Woori IO.

When is OSRH expected to complete the Woori IO acquisition?

OSRH expects to complete the Stock Purchase Agreement for Woori IO by the end of October, which will include details about their partnership with a major technology company.

How is OSRH using the proceeds from its equity financing?

OSRH is investing the financing proceeds directly into drug R&D pipeline development, medical device initiatives, and digital asset ecosystems.